Marker IDs More Lymph Node Mets in Endometrial Cancer

Share this content:
Marker IDs More Lymph Node Mets in Endometrial Cancer
Marker IDs More Lymph Node Mets in Endometrial Cancer

WEDNESDAY, March 23, 2016 (HealthDay News) -- In apparent uterine-confined endometrial cancer, the addition of indocyanine green (ICG) and near-infrared imaging to pelvic sentinel lymph node (SLN) mapping with isosulfan blue (ISB) improves detection of lymph node metastasis, according to a new study. The findings were expected to be presented at the annual meeting of the Society of Gynecologic Oncology, held from March 19 to 22 in San Diego.

Robert W. Holloway, M.D., of the Florida Hospital Cancer Institute in Orlando, and colleagues randomly assigned 200 patients with endometrial cancer to pelvic sentinel lymph node mapping with either ISB plus ICG (180 patients) or ISB alone (20 patients).

The researchers found that ISB detection of SLNs did not differ for the ISB + ICG versus the ISB alone group (P = 0.35). SLN mapping for the ISB + ICG group (180 patients), compared with all patients receiving ISB (200 patients), detected bilateral SLNs for 83.9 versus 40 percent, unilateral SLNs for 12.2 versus 36 percent, and no SLNs for 3.9 versus 24 percent (P < 0.001). Positive SLNs were found in 39 patients in the ISB + ICG group (21.7 percent) and two patients in the ISB alone group (10 percent). There was one false-negative SLN (sensitivity, 97.5 percent; negative predictive value, 99.3 percent; false-negative rate, 2.5 percent).

"ISB + ICG and near-infrared imaging detected more SLN and LN metastases than ISB alone in this phase III trial," the authors write. "SLN mapping with ICG + ISB had excellent sensitivity for detection of metastasis."

Training honoraria from Intuitive Surgical Inc. and speaker honoraria from Astra Zeneca and Jannsen were disclosed.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »